ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2023. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $9,737 | +16.7% | 236,913 | +32.5% | 0.00% | +50.0% |
Q1 2024 | $8,347 | -23.0% | 178,773 | -21.2% | 0.00% | -60.0% |
Q4 2023 | $10,844 | +152.0% | 226,742 | +87.9% | 0.01% | +66.7% |
Q3 2023 | $4,303 | -8.7% | 120,693 | +18.2% | 0.00% | 0.0% |
Q2 2023 | $4,711 | +28.2% | 102,141 | +11.4% | 0.00% | +50.0% |
Q1 2023 | $3,676 | -36.3% | 91,667 | -26.4% | 0.00% | -33.3% |
Q4 2022 | $5,772 | -99.9% | 124,587 | +7.8% | 0.00% | -40.0% |
Q3 2022 | $4,788,000 | +299.7% | 115,590 | +475.8% | 0.01% | +400.0% |
Q2 2022 | $1,198,000 | -15.8% | 20,075 | +2.4% | 0.00% | 0.0% |
Q1 2022 | $1,423,000 | -63.9% | 19,602 | -58.2% | 0.00% | 0.0% |
Q4 2021 | $3,940,000 | +827.1% | 46,860 | +893.8% | 0.00% | – |
Q3 2021 | $425,000 | -81.7% | 4,715 | -80.7% | 0.00% | -100.0% |
Q2 2021 | $2,326,000 | -71.5% | 24,380 | -66.0% | 0.00% | -75.0% |
Q1 2021 | $8,161,000 | +150.6% | 71,676 | +204.7% | 0.00% | +100.0% |
Q4 2020 | $3,257,000 | -59.4% | 23,524 | -75.9% | 0.00% | -60.0% |
Q3 2020 | $8,025,000 | +197.7% | 97,631 | +183.2% | 0.01% | +150.0% |
Q2 2020 | $2,696,000 | -60.0% | 34,470 | -77.3% | 0.00% | -60.0% |
Q1 2020 | $6,742,000 | +39.4% | 151,772 | +34.1% | 0.01% | +66.7% |
Q4 2019 | $4,835,000 | +318.3% | 113,211 | +318.6% | 0.00% | +200.0% |
Q3 2019 | $1,156,000 | -48.5% | 27,047 | -23.5% | 0.00% | 0.0% |
Q2 2019 | $2,243,000 | -56.5% | 35,334 | -52.4% | 0.00% | -66.7% |
Q1 2019 | $5,152,000 | +1623.1% | 74,264 | +981.9% | 0.00% | – |
Q4 2018 | $299,000 | -86.0% | 6,864 | -75.4% | 0.00% | -100.0% |
Q3 2018 | $2,133,000 | +149.8% | 27,949 | +151.7% | 0.00% | 0.0% |
Q2 2018 | $854,000 | +43.0% | 11,103 | -5.1% | 0.00% | – |
Q1 2018 | $597,000 | +41.8% | 11,705 | +28.9% | 0.00% | – |
Q4 2017 | $421,000 | +127.6% | 9,083 | +160.3% | 0.00% | – |
Q3 2017 | $185,000 | +8.8% | 3,489 | +27.2% | 0.00% | – |
Q2 2017 | $170,000 | -92.6% | 2,742 | -91.9% | 0.00% | -100.0% |
Q1 2017 | $2,303,000 | +419.9% | 33,985 | +439.2% | 0.00% | – |
Q4 2016 | $443,000 | -82.2% | 6,303 | -82.0% | 0.00% | -100.0% |
Q3 2016 | $2,485,000 | +1953.7% | 35,043 | +1314.7% | 0.00% | – |
Q2 2016 | $121,000 | -61.9% | 2,477 | -50.8% | 0.00% | – |
Q1 2016 | $318,000 | +90.4% | 5,039 | +236.6% | 0.00% | – |
Q4 2015 | $167,000 | -85.3% | 1,497 | -87.4% | 0.00% | -100.0% |
Q3 2015 | $1,139,000 | -75.6% | 11,862 | -74.1% | 0.00% | -80.0% |
Q2 2015 | $4,666,000 | +10268.9% | 45,745 | +6123.8% | 0.01% | – |
Q1 2015 | $45,000 | +55.2% | 735 | +9.7% | 0.00% | – |
Q4 2014 | $29,000 | +107.1% | 670 | +174.6% | 0.00% | – |
Q3 2014 | $14,000 | +133.3% | 244 | +105.0% | 0.00% | – |
Q2 2014 | $6,000 | -33.3% | 119 | -34.3% | 0.00% | – |
Q1 2014 | $9,000 | – | 181 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |